주요 콘텐츠로 건너뛰기

귀하의 브라우저가 완벽하게 지원되지 않습니다. 옵션이 있는 경우 최신 버전으로 업그레이드하거나 Mozilla Firefox, Microsoft Edge, Google Chrome 또는 Safari 14 이상을 사용하세요. 가능하지 않거나 지원이 필요한 경우 피드백을 보내주세요.

이 새로운 경험에 대한 귀하의 의견에 감사드립니다.의견을 말씀해 주세요 새 탭/창에서 열기

Elsevier
엘스비어와 함께 출판

Editorial Policy General Information

마지막 업데이트: | 2023년 5월 2일

Elsevier’s Clinical Editorial team develops clinically-based drug information content through a peer-reviewed process. The peer-review process represents an objective analysis of clinically-relevant drug information. The content development cycle mimics the peer-review process in effect for major scientific publications. In general, editorial content follows the style of other peer-reviewed medical publications, including the style of the American Medical Association Manual of Style: A Guide for Authors and Editors. Modifications to this style are standardized within internal policy and reflect the needs of database production and point-of-care information requirements of healthcare providers.

Elsevier’s Clinical Editorial team is composed of clinical pharmacists who have undergone extensive training. Many have experience in hospitals and retail pharmacy chains, have held academic positions with universities, and have attained board certification in specialty areas. They have received awards, authored original papers, had work featured in numerous scientific journals, and have published books targeted to healthcare professionals.

The Clinical Editorial team includes the following basic categories:

  • Editor-in-Chief

  • Managing Editor

  • Therapeutic Area Specialist

  • Pharmacotherapy Specialist

  • Drug Information Specialist

  • Linguistic Assistant

To ensure the most up-to-date drug information is included, the Clinical Editorial team updates clinical content in a “real time” format rather than working against pre-determined deadlines. This allows for tremendous flexibility when establishing priorities for client updates and the ability to be responsive to late breaking medical news, trials, and previously unannounced drug label changes.

Content updates to the database include: new FDA-approved drugs, new non-prescription and herbal therapies, newly published information regarding FDA label changes and relevant clinical studies affecting off-label utilization. Each member of the editorial staff is responsible for monitoring certain therapeutic categories for pertinent information to be included in the database.

엘스비어의 약물 정보 솔루션이 여러분이 속한 의료 팀에 어떠한 지원을 제공할 수 있는지 알아보세요

미소 짓는 여성 세로형